Roger S. Kirby John D. McConnell John M. Fitzpatrick
The spectrum of available treatment options for benign prostatic hyperplasia (BPH) is matched by the spectrum of disease severity, and with up to 90% of men in their 80s suffering from BPH to some extent, it is imperative that patients are offered the full range of options to manage the disease.
Pharmacologic therapies available for the treatment of lower urinary tract symptoms secondary to BPH include alpha-adrenoceptor antagonists, such as terazosin, doxazosin, alfuzosin and tamsulosin, and the 5-alpha-reductase inhibitors, finasteride and dutasteride. Other strategies, such as...
The spectrum of available treatment options for benign prostatic hyperplasia (BPH) is matched by the spectrum of disease severity, and with up to 9...
Technology seems to be an integral part of modern living. Urologists have over the years embraced new technological advances for patient beneft. On some occasions, however, the initial enthusiasm in something new has failed to endure rigorous scientifc scrutiny. Thus, while being technological leaders, we urologists know better than most other surgical speci- ties that what is new is not necessarily good. This textbook is aimed at urologists and surgeons at all levels and has contributions from international experts. The topics vary from robotics to lasers to single port laparoscopy. The...
Technology seems to be an integral part of modern living. Urologists have over the years embraced new technological advances for patient beneft. On so...
